Prosecution Insights
Last updated: November 15, 2026
Application No. 18/557,802

METHOD FOR PROVIDING INFORMATION FOR PREDICTING THERAPEUTIC RESPONSIVENESS TO IMMUNE CHECKPOINT INHIBITOR IN CANCER PATIENT USING MULTIPLE IMMUNOHISTOCHEMICAL STAINING

Final Rejection §101
Filed
Oct 27, 2023
Priority
Apr 29, 2021 — RE 10-2021-0055916 +1 more
Examiner
GIERE, REBECCA M
Art Unit
1677
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Theranovis Co. Ltd.
OA Round
2 (Final)
74%
Grant Probability
Favorable
3-4
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
385 granted / 522 resolved
+13.8% vs TC avg
Strong +32% interview lift
Without
With
+32.5%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
31 currently pending
Career history
553
Total Applications
across all art units

Office Action

§101
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Status of Claims Claims 3-4 and 6 have been cancelled. Claims 1-2, 5 and 7-9 are pending and have been examined. Response to Arguments Applicant’s arguments filed 08/07/2026 have been considered and are found to be persuasive. As persuasively argued on pages 5-9 of Applicant’s reply, Sundar in view of Agus fail to teach measuring an expression level of an immune checkpoint molecule from the image in each of a cancer cell and an immune cell as a tumor proportion score (TPS) or a combined positive score (CPS) through phenotyping performed using a machine learning model; and determining that the cancer patient has a high treatment response to the immune checkpoint inhibitor when the TPS or CPS is at least 15. However, the claims remain unpatentable as the claims are found to be drawn to patent ineligible subject matter, as described below. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1-2, 5 and 7-9 are rejected under 35 U.S.C. 101 because the claimed invention is directed to abstract ideas without significantly more. Claim 1 recites, obtaining, performing, measuring an expression level and determining that the cancer patient has a high treatment response to the immune checkpoint inhibitor when the TPS or CPS is at least 15. The claimed limitation of using the measured expression level as a TPS or CPS and determining that the patient has a high treatment response to the immune checkpoint inhibitor when the TPS or CPS is at least 15 is a concept performed in the human mind belonging to the mental process grouping of the abstract ideas judicial exception (see MPEP § 2106.04(a)(2), subsection III). The judicial exception is not integrated into a practical application, such as requiring an additional element or a combination of additional elements in the claim to apply, rely on, or use the judicial exception in a manner that imposes a meaningful limit on the judicial exception (see MPEP § 2106.05(a)-(c), (e)-(h)) such that the invention does not preempt every observance of the natural phenomenon itself. Eligibility Step 1: Claim 1 is directed to a method of determining a treatment response to an immune checkpoint inhibitor. Methods are one of the eligible statutory categories for invention (STEP 1: YES). However, eligibility of the claim is not self-evident, and therefore analysis must proceed to Step 2. Eligibility Step 2A, Prong One: The claim recites using the measured expression level as a TPS or CPS to determine that the cancer patient has high treatment response when the TPS or CPS in at least 15, which is an abstract mental concept that belongs to enumerated group (III) of the Abstract Idea Groupings described in MPEP § 2106.04(a)(2). Therefore, the claims recite at least one judicial exception (STEP 2A, Prong One: YES). Eligibility Step 2A, Prong Two: According to Step 2A, Prong Two, set forth in MPEP 2106.04 II A (2), the claims are next evaluated with respect to whether the judicial exception is integrated into a practical application. This analysis turns to the additional steps/elements recited within the claim. Claims 5 and 7 recite how the multiplex immunohistochemistry is performed. Claim 8 recites additional steps for training the machine learning model. Regarding the additional steps cited in claim 1, obtaining a tumor sample, performing multiplex immunohistochemistry and measuring an expression level is insufficient to integrate the judicial exception(s) because the purpose is merely to obtain data. This does not go beyond insignificant presolution activity, i.e., a mere data gathering step necessary to use the correlation, similar to the fact pattern in In re Grams, 888 F.2d 835 (Fed. Cir. 1989) and Ariosa Diagnostics, Inc. v. Sequenom, Inc. (Fed. Cir. 2015). There are no other additional elements that apply, rely on or use the judicial exception such to integrate it into a practical application. For example, there are no additional elements that apply the abstract idea judicial exception to a particular treatment or which utilize a particular machine; there are no additional elements that effect a transformation; and, there are no additional elements that apply the judicial exception in some other meaningful way beyond generally linking it to a field, namely, determining a treatment response. At best, the claimed combination amounts to improvements to the abstract idea of determining that the cancer patient has a high treatment response to the immune checkpoint inhibitor, rather than to any specific technology. See MPEP 2106.05(a). In this way the claims, as drafted, do not integrate the judicial exception into a practical application that would overcome monopolizing the exception. ((STEP 2A, Prong Two: NO). Eligibility Step 2B: Lastly, the examiner cites publications within the field of technical expertise, that demonstrate the well-understood, routine, conventional nature of the additional element(s). Regarding the steps/elements recited in addition to using the measured expression level, Sundhar et al. (IDS, previously cited) teaches obtaining a sample of tumor tissue from a cancer patient; performing multiplex immunohistochemistry on the sample of tumor tissue to obtain an image in the form of staining by staining antibodies specific for each of a cancer cell and an immune cell (see page 3, Figure 1 caption); and measuring an expression level of an immune checkpoint molecule from the image (see page 2, PD-L1 immunochemistry section and Figure 1/caption). Therefore, the steps/elements recited in addition to the judicial exception were all well understood, routine, conventional activities in the field of determining treatment response prior to filing the application at hand (STEP 2B: NO). The claimed steps/elements recited in addition to the judicial exception(s), alone or in combination, do not amount to significantly more than that which was routine and conventional in the art prior to filing. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to REBECCA M GIERE whose telephone number is (571)272-5084. The examiner can normally be reached M-F 8:30-4:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bao-Thuy L Nguyen can be reached at 571-272-0824. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /REBECCA M GIERE/Primary Examiner, Art Unit 1677
Read full office action

Prosecution Timeline

Oct 27, 2023
Application Filed
May 07, 2026
Non-Final Rejection mailed — §101
Aug 07, 2026
Response Filed
Oct 20, 2026
Final Rejection mailed — §101 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790574
IN VITRO ANALYSIS DIAGNOSTIC INSTRUMENT, AND MICROFLUIDIC CHIP AND METHOD FOR SORTING AND ENRICHING CIRCULATING TUMOR CELLS
3y 3m to grant Granted Nov 10, 2026
Patent 12791569
COMPONENT MEASUREMENT SYSTEM AND COMPONENT MEASUREMENT DEVICE
3y 1m to grant Granted Nov 10, 2026
Patent 12791554
Microfluidic System and Method for Real-Time Measurement of Antibody-Antigen Binding and Analyte Detection
2y 8m to grant Granted Nov 10, 2026
Patent 12782352
ALLERGEN-IMMOBILIZED CARRIER AND METHOD OF DETECTING ALLERGEN-SPECIFIC ANTIBODY
3y 3m to grant Granted Nov 03, 2026
Patent 12782346
Combined Immunoassay and Magnetic Immunoassay Methods for Extended Range of Sensitivity
2y 5m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
74%
Grant Probability
99%
With Interview (+32.5%)
Moderate
PTA Risk
Based on 522 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month